---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-22-024362"
form_type: "8-K"
ticker: "CRDF"
cik: "0001213037"
company_name: "Cardiff Oncology, Inc."
filed_at: "2022-09-06T23:59:59+00:00"
generated_at: "2026-06-23T15:02:51.731268+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Cardiff Oncology announces ESMO 2022 posters showing onvansertib overcomes irinotecan resistance in RAS-mutated mCRC

## Summary
- Abstract 366P: Onvansertib overcomes irinotecan resistance in RAS-mutated metastatic colorectal cancer in vivo and in patients (EAP).
- Abstract 397P: Early ≥90% decrease in KRAS MAF after one cycle predicts higher ORR and longer PFS in ongoing Phase 1b/2 trial.
- Additional findings from EAP and trial data to be released during ESMO, subject to embargo policies.
- Conference call and webcast on Sept 12, 2022 at 4:30 PM ET to discuss clinical and corporate update.

## SEC filing metadata
- accession: 0001628280-22-024362
- form_type: 8-K
- ticker: CRDF
- cik: 0001213037
- company_name: Cardiff Oncology, Inc.
- filed_at: 2022-09-06T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1213037/000162828022024362/0001628280-22-024362-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1213037/000162828022024362/crdf-20220906.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-22-024362
- JSON: https://secwatch.observer/filing/0001628280-22-024362.json
- Plain text: https://secwatch.observer/filing/0001628280-22-024362.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.